Table 3 Efficacy of rituximab (RTX) treatment in each subgroup of Thai NMOSD patients (n = 39).
From: Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
Outcomes | Pre RTX | Post RTX | p value* |
|---|---|---|---|
NMOSD (n = 39) | |||
ARR†, times/year; median (IQR) | 0.92 (0.68–1.78) | 0 (0–0.17) | < 0.001 |
EDSS scores; median (IQR) | 4.5 (3.0–6.0) | 4.0 (2.0–5.5) | < 0.001 |
Classified by maintenance treatment regimens | |||
A fixed 6-month time point regimen subgroup (n = 15) | |||
ARR†, times/year; median (IQR) | 0.95 (0.67–2.02) | 0 (0–0.11) | 0.005 |
EDSS scores; median (IQR) | 5.0 (3.0–6.5) | 4.5 (2.5–5.5) | 0.042 |
A CD19-based reinfusion regimen subgroup (n = 24) | |||
ARR†, times/year; median (IQR) | 0.92 (0.71–1.33) | 0 (0–0.23) | < 0.001 |
EDSS scores; median (IQR) | 4.3 (3.0–6.0) | 3.3 (2.0–5.0) | 0.002 |
Classified by history of previous DMTs or IS | |||
Treatment-naive subgroup (n = 13) | |||
Number of relapses; median (IQR) | 2 (1–2.5) | 0 (0–0.5) | 0.003 |
ARR†, times/year; median (IQR) | – | 0 (0–0.22) | – |
EDSS scores; median (IQR) | 5.0 (3.8–6.0) | 4.0 (2.0–5.8) | 0.027 |
Treatment-experienced subgroup (n = 26) | |||
Number of relapses; median (IQR) | 4 (2–7) | 0 (0–0.3) | < 0.001 |
ARR†, times/year; median (IQR) | 0.89 (0.69–1.20) | 0 (0–0.22) | < 0.001 |
EDSS scores; median (IQR) | 4.3 (2.9–6.1) | 3.8 (2.0–5.5) | 0.003 |
